Key Points
- AI drug discovery firm Iambic Therapeutics has submitted paperwork for a Nasdaq IPO under ticker symbol “IAM”, with backing from Nvidia and Qatar’s sovereign wealth fund
- The biotech company seeks to secure as much as $100 million to push forward its cancer treatment pipeline
- The company’s primary candidate IAM1363 represents an oral HER2 inhibitor currently undergoing early-phase clinical testing for solid tumors
- Since launching in 2019, Iambic has secured $461.8 million in funding and established collaborations with AbbVie, Takeda, and additional pharmaceutical partners
- The biotech sector is experiencing strong IPO performance in 2026, with five top-performing listings all from biotechnology companies
Iambic Therapeutics, a drug discovery enterprise leveraging artificial intelligence technology with support from Nvidia and Qatar’s sovereign investment fund, submitted documentation for a United States public offering on Monday. The biotech firm, headquartered in San Diego, intends to debut on the Nasdaq exchange using ticker symbol “IAM.”
According to Renaissance Capital, the proposed offering aims to generate up to $100 million. The company’s regulatory filing did not specify a pricing range for shares.
The Company’s Focus and Operations
Established in 2019 under the original name Entos, Iambic combines artificial intelligence capabilities with automated chemistry and biological systems to identify small-molecule therapeutic compounds. The company concentrates on developing treatments for solid tumor cancers.
The firm’s flagship development candidate, designated IAM1363, is an investigational oral HER2 inhibitor. This compound is presently undergoing Phase 1/1b early-stage clinical evaluation for various solid tumors, including breast cancer cases.
Additional programs designated IAM217 and IAM-C1 are still in preclinical stages. The company intends to allocate funds from the public offering to move all three therapeutic candidates forward through clinical development phases.
The biotech has accumulated approximately $461.8 million in investment capital from its inception. Its investor roster includes Nvidia, the Qatar Investment Authority, Catalio, Nexus Ventures, and Coatue Management.
Coinciding with its IPO filing, Iambic revealed a multi-year strategic partnership with AbbVie focused on accelerating AI-powered identification of small molecule treatments. The firm maintains active collaborations with Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, and Bayer as well.
The underwriting syndicate for this offering consists of J.P. Morgan, Jefferies, BofA Securities, and Citigroup.
Biotech Sector Leads IPO Performance
Iambic joins several other companies pursuing public listings this autumn. Pharmaceutical developers Retension Pharmaceuticals and TRex Bio submitted their US IPO filings on Friday. ADARx Pharmaceuticals commenced its investor roadshow on the identical day Iambic submitted its documents.
Biotechnology listings have demonstrated resilience in 2026 even as the broader IPO landscape faces challenges. Market headwinds including the Iran conflict, climbing bond yields, and increasing interest rates have created difficulties across multiple industries.
According to Matt Kennedy, senior strategist at Renaissance Capital, the five strongest-performing IPOs this year with offerings exceeding $50 million all come from the biotechnology sector. He identified clinical advancement milestones and merger and acquisition momentum as primary catalysts.
Market observers note that biotech public offerings have stayed relatively protected from wider market volatility. Active acquisition interest from major pharmaceutical companies has bolstered investor sentiment toward the sector.
Iambic’s submission contributes to what appears to be a busy autumn period for biotech public market entries.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
